# Mindera Health

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/mindera-health

- Industry: Medical Devices & Equipment
- Headquarters: Vista, US
- Website: www.minderahealth.com
- Total disclosed funding: $13M
- Latest round: Series A (May 12, 2021)
- Investors on record: 3

## About

Mindera Health, based in the US, specializes in precision medicine solutions for dermatological conditions, focusing on advanced testing for psoriasis. Its innovative approaches enhance patient care through data-driven treatment decisions.Founded in 2013 and headquartered in Vista, US, Mindera Health develops precision medicine technologies targeted at dermatological conditions. The company pivoted from its original focus to specialize in psoriasis treatment. The firm has raised a total of USD 12.00 mn, with its latest funding round being a Series A in May 2021, co-led by Mountain Group Partners, Rockmont Capital Partners, and Scientific Health Development. The company's founder, Tobin Dickerson, has a history of entrepreneurial ventures, while the current leadership includes CEO George Mahaffey and Ron Rocca.Mindera Health specializes in precision medicine solutions focused on dermatological conditions, particularly psoriasis. Their core product, the Mind.Px™ test, utilizes advanced technology to collect and analyze thousands of RNA transcripts via a simple, non-invasive, penny-sized patch applied to the skin. This innovative approach enables healthcare providers to make data-driven decisions tailored to individual patients, enhancing treatment efficacy and patient outcomes. The Mind.Px™ test is designed for use by dermatologists and healthcare providers, effectively serving patients who require biologic treatments for psoriasis. Mindera Health's products are positioned to cater primarily to markets in North America and Europe, where the demand for precision medicine in dermatology continues to grow.Mindera Health generates revenue through the provision of its Mind.Px™ test and associated services to healthcare providers and facilities involved in treating psoriasis patients. Transactions typically occur on a B2B basis, where healthcare providers order the Mind.Px™ test for their patients, and the results inform treatment decisions regarding biologic therapies. The pricing structure is designed to facilitate partnerships with clinics and hospitals, ensuring accessibility and integration into their treatment protocols. By leveraging the efficacy of the Mind.Px™ test, Mindera Health strengthens its relationships with medical professionals, ultimately driving revenue through the enhanced patient outcomes that result from more accurate and targeted biologic treatments. The company actively seeks to expand its reach within both established and emerging markets for dermatological care.Mindera Health intends to utilize the USD 12.00 mn raised in its Series A funding round for product improvement. The company is focused on launching new enhancements to the Mind.Px™ test and expanding its footprint into additional markets in North America and Europe by 2023. The funding will support research and development initiatives aimed at refining the product and solidifying partnerships within the healthcare sector.

## Funding rounds

- Series A, May 12, 2021, $12M — Rockmont Capital Partners, Mountain Group Partners, Scientific Health Development
- Seed, Oct 13, 2015, $1M — Scientific Health Development

## Investors

- Scientific Health Development (https://capitalatlas.ai/funds/scientific-health-development) — Seed, Series A
- Rockmont Capital Partners (https://capitalatlas.ai/funds/rockmont-capital-partners) — Series A
- Mountain Group Partners (https://capitalatlas.ai/funds/mountain-group-partners) — Series A